Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Galapagos NV Major Shareholding Notification 2019

Oct 28, 2019

3954_iss_2019-10-25_d8e98b8e-431e-4c7e-b66b-419d75c6e663.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

Galapagos receives transparency notification from Wellington Management Group LLP

Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from Wellington Management Group LLP.

Pursuant to Belgian transparency legislation1 , Galapagos received a transparency notification on 22 October 2019 from Wellington Management Group LLP, who indicated that, following a disposal of ordinary shares, the remaining 3,079,573 Galapagos ordinary shares held by its entirelycontrolled subsidiary Wellington Management Company LLP represent 4.97% of the current 61,953,831 outstanding Galapagos shares and thus, with the ordinary shares portion of its total position, crossed below the 5% threshold of Galapagos' voting rights on 8 October 2019. In addition, through its wholly owned subsidiary Wellington Management Company LLP, it now also holds 615,676 American Depositary Shares and 8,322 equity swaps with expiration in 2020, bringing the new total number of voting rights for Wellington Management Group to 3,703,571, which represents 5.98% of total outstanding shares. The full transparency notice is available on the Galapagos website.

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in latestage development in multiple diseases. The company's pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos' ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors: Media: Elizabeth Goodwin Carmen Vroonen

Sofie Van Gijsel Evelyn Fox +32 485 19 14 15 +31 6 53 591 999

VP IR Senior Director Communications +1 781 460 1784 +32 473 824 874

Director IR Director Communications [email protected] [email protected]

1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market